Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label active-controlled study of SRSD107 versus enoxaparin for venous thromboembolism prevention after total knee arthroplasty
MOH_2026-07-18_016941Phase 2Not yet recruiting
- Sponsor
- Sirius Therapeutics
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SRSD107 and enoxaparin in venous thromboembolism (VTE) (4 arms), sponsored by Sirius Therapeutics. Primary endpoints: Efficacy of SRSD107 versus enoxaparin and Safety of SRSD107 versus enoxaparin. Planned start May 2026; status: not yet recruiting.
02
Drugs
SRSD107enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2026-07-18_016941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-18_016941.